Stock comparison
ANI Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANIP
ANI Pharmaceuticals
Market cap
$1.88B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANIP | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 75B | IDXX |
| Benjamin Graham | 59D | 80A | IDXX |
| Philip Fisher | 58C | 75B | IDXX |
| Peter Lynch | 71C | 71B | Tie |
| Joel Greenblatt | 44D | 83C | IDXX |
| Charlie Munger | 47D | 87A | IDXX |
| Terry Smith | 50D | 84A | IDXX |
Side-by-side metrics
| Metric | ANIP | IDXX |
|---|---|---|
| Market cap | $1.88B | $44.12B |
| P/E (TTM) | 18.5x | 39.0x |
| EV/EBIT | 22.4x | 31.6x |
| ROIC (TTM) | 8.17% | 40.66% |
| Gross margin | 65.94% | 62.05% |
| Net margin | 9.71% | 24.63% |
| Revenue CAGR 5y | 42.18% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.6x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANIP leads on
- Revenue CAGR 5y42.18%vs 7.56%+82%
- P/E (TTM)18.5xvs 39.0x+53%
- EV/EBIT22.4xvs 31.6x+29%
- Debt / Equity0.6xvs 0.7x+16%
IDXX leads on
- Market cap$44.12Bvs $1.88B+96%
- ROIC (TTM)40.66%vs 8.17%+80%
- Net margin24.63%vs 9.71%+61%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.